Arix Shepherds Atox $30m Funding Amid High Hopes For Start-up's Lead Asset

Its investment in Atox Bio's $30m Series F financing round added the 12th company to Arix's portfolio, hitting a target set at its February IPO. Atox’s late-stage peptide is designed to modulate a patient’s response to severe infections.

H1N1
Atox Bio Plans To Target Multiple |nfectious Diseases • Source: Shutterstock

Late-stage clinical biotech Atox Bio Inc. told Scrip its successful $30m Series F financing gave it adequate funding to progress lead therapeutic candidate reltecimod in Phase III for necrotizing soft tissue infections and Phase II in acute kidney injury, and that further indications will also be targeted for the asset.

The funding round, completed Dec. 4, was led by Arix Bioscience PLC, which directly invested $8m and will now place...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.